Publications by authors named "Tuqa Y Alharbi"
Article Synopsis
- Hypertrophic obstructive cardiomyopathy (HOCM) is a genetic heart condition that leads to thickening of the heart muscle and obstructs blood flow from the left ventricle, making treatment challenging.
- Mavacamten, a new drug that inhibits cardiac myosin, has shown significant effectiveness in reducing left ventricular outflow tract (LVOT) gradients and improving other heart-related measurements in patients with HOCM, based on a meta-analysis of two randomized controlled trials involving 332 patients.
- The drug not only demonstrated beneficial effects but also had a favorable safety profile, suggesting it could change how HOCM is managed, although further long-term studies are needed to confirm its effectiveness and safety.
